Page 13 - Dr Reddy’s Laboratories
Dr Reddy's gains 4% as API Srikakulam plant gets USFDA clearance
The stock was up nearly 4% to Rs 2,010 on the BSE in early morning trade after the company said the US health regulator has completed the audit of its API Srikakulam plant (SEZ) with no observations.
 "Dr Reddy's gains 4% as API Srikakulam plant gets USFDA clearance")
Dr Reddy's names ex-Teva official Erez Israeli as COO, global generics head
BS ReporterHyderabad, 29 March. Dr Reddy's Laboratories Limited today announced a change in the senior leadership team. The company has appointed former president and CEO of Enzymotec, Erez Israeli as the chief operating officer and global head of generics and PSAI(pharmaceutical services and active ingredients).He will replace Abhijit Mukherjee, who is retiring on March 31, 2018 after a 15-year stint in Dr Reddy's. In a career spanning 25 years, Israeli has held leadership positions that have contributed significantly to the performance of companies he worked for, Dr Reddy's said. Prior to Enzymotec, he completed 23 years with Teva Pharmaceuticals Limited, where he held several positions of responsibility including vice president, marketing and sales for North America, vice president Asia Operations, President Teva API, group executive vice president, head of global quality, and president and CEO growth markets.Israeli will join the company on April 2. He will report to Dr Reddy's ...
 "Dr Reddy's names ex-Teva official Erez Israeli as COO, global generics head")
Dr Reddy's gets 5 observations from US FDA for API unit at Hyderabad
The company said plant-3 at Bollaram on the city outskirts has recieved these observations upon completion of an inspection
 "Dr Reddy's gets 5 observations from US FDA for API unit at Hyderabad")
Dr Reddy's chairman, COO added as defendants in US class action lawsuit
The company believes that the asserted claims are without merit and intends to vigorously defend itself against the allegations
Dr Reddy's Labs acquiring products but not marketing most of them
In 5 of 9 asset buys made in 2014-16, Dr Reddy's is yet to put them to use; it spent Rs 38.82 bn on the acquisitions
Dr Reddy's falls for fourth straight day on poor Q3 results
The stock was trading 3.4% lower at Rs 2,233, down 13% in past four trading days from Rs 2,562 on January 24, as compared to 0.67% decline in the S&P BSE Sensex.
Dr Reddy's Labs Q3 net profit drops 29%; Dalal Street still awaits triggers
Resolution of warning letters issued by FDA and clarity on launches key
 "Dr Reddy's Labs Q3 net profit drops 29%; Dalal Street still awaits triggers")
Dr Reddy's Q3 profit down 29% at Rs 3.3 bn on higher price erosion
BS ReporterHyderabad, 25 January: Indian pharmaceutical major Dr Reddy's Laboratories Limited has reported a 29 percent decline in consolidated net profit at Rs 3.34 billion for the quarter ended December 2017 on the back of higher price erosion, increased competition and the impact of adverse foreign exchange in the US and European markets.However, the company was able to post a 3 percent increase in consolidated revenues at Rs 38.06 billion during the third quarter under review as compared with Rs 37.07 billion in the corresponding quarter previous year. "We had a satisfactory third quarter performance with all our key markets performing well. We recorded sequential revenue growth of 7 percent despite continuing challenges such as price erosion in the USA. Our first-cycle NDA approval of Impoyz is a significant milestone in the commercialisation o four proprietary products pipeline. We will continue our focus on operational excellence and controlling of SG&A(selling, general and
 "Dr Reddy's Q3 profit down 29% at Rs 3.3 bn on higher price erosion")
Dr Reddy's Q3 profit tumbles 38% as sales decline on US pricing pressure
Net profit was Rs 3.03 billion in the third quarter ended December 31
 "Dr Reddy's Q3 profit tumbles 38% as sales decline on US pricing pressure")
Dr Reddy's falls on buzz of issues raised in EIR for Duvvada plant
The stock dipped 4.5% to Rs 2,299 on the BSE in intra-day trade.
Dr Reddy's settles blister package case with US govt for $5 mn
BS ReporterHyderabad, 19 December: Indian drug major Dr Reddy's Laboratories Limited has reached a settlement with the US Government agencies for $ 5 million in a six year old case regarding complaints of potential harm from the package of blister-packed prescription products to children.In June last year US Consumer Product Safety Commission(CPSC) has requested the US Department of Justice to impose civil penalty on Dr Reddy's for alleged violations of provisions related to child resistant packaging in at least five prescription drugs.While disagreeing with these allegations, the company on Tuesday said it has chosen to settle the matter in order to avoid any unnecessary costs and the distractions of prolonged litigation. In a joint filing by the parties, Dr Reddy's and the US Department of Justice agreed to the settlement of the action without any adjudication of any issue of fact or law.In an investigation conducted between 2008 and 2012, US CPSC held that the company sold ...
Plant clearance removes overhang for Dr Reddy's
Nod to Bachupally plant raises hopes for clearance of its Srikakulam unit
Dr Reddy's rallies after receiving EIR from USFDA
The stock was trading 3% higher at Rs 2,498, after rallying 10% in intra-day trade as the company received EIR from the USFDA for Vishakhapatnam facility, but the inspection has not closed.
Dr Reddy's prospects hinge on FDA clearances
Non-US geographies grow well in Q2; cost controls support profitability
Dr Reddy's up 4% after receiving EIR from USFDA for Srikakulam Unit I
In past one month, the stock has outperformed the market by surging 17% as compared to 2% decline in the S&P BSE Sensex
Dr Reddy's strong drug pipeline comes to the fore
Dr Reddy's was the biggest gainer among the Sensex stocks as brokerage upgrades as well as US FDA approval for one of its plants saw the stock move up nearly 7.5 per cent. The easing regulatory pressures and plant approvals helps the company launch new products and capitalise on niche opportunities. This is the second unit that has received the establishment inspection report after Miryalaguda (Telengana) got the green signal from the US FDA in February this year. The receding plant related worries means that the street will now turn to the company's product portfolio and launch timeline to gauge the revenue potential in the US market. Deepak Malik of Edelweiss Securities believes that a large and increasing complex generics pipeline in the US, tripling of biosimilar revenues to $150 million over the FY18-20 period will lead to a 53 per cent growth in the company's net profit over the same period. Analysts believe that a strong product pipeline (including niche opportunities) should .
Dr Reddy's shares jump 7.5%; m-cap rises by Rs 2,864 cr
On NSE, shares of the company soared 7.42% to close at Rs 2,486.55
Dr Reddy's Labs gains as Srikakulam SEZ Unit II get EIR from USFDA
The stock moved higher by nearly 7% to Rs 2,466 on BSE in an otherwise weak market
 "Dr Reddy's Labs gains as Srikakulam SEZ Unit II get EIR from USFDA")
US FDA makes 3 observations after inspecting Dr Reddy's UK plant
Form 483 issued to the firm's management over violation of regulatory norms
Dr Reddy's falls as firm gets 6 observations in Duvvada facility audit
The stock dipped 7% to Rs 2,066 on NSE in intra-day trade